PureTech Health (PRTC) Competitors

PureTech Health logo
$17.42 0.00 (0.00%)
As of 11/6/2026

PRTC vs. RARE, PGEN, NBTX, NVAX, and IMCR

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), Precigen (PGEN), Nanobiotix (NBTX), Novavax (NVAX), and Immunocore (IMCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical currently has a consensus target price of $29.79, suggesting a potential upside of 87.36%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

PureTech Health has lower revenue, but higher earnings than Ultragenyx Pharmaceutical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$673M2.41-$575M-$5.19N/A
PureTech Health$4.66M91.01-$109.74MN/AN/A

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 0 mentions for PureTech Health. Ultragenyx Pharmaceutical's average media sentiment score of 0.62 beat PureTech Health's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company Overall Sentiment
Ultragenyx Pharmaceutical Positive
PureTech Health Neutral

PureTech Health has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -71.78%.

Company Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical-71.78% N/A -39.70%
PureTech Health N/A N/A N/A

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Precigen?

Precigen (NASDAQ:PGEN) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

In the previous week, Precigen had 6 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Precigen and 0 mentions for PureTech Health. Precigen's average media sentiment score of 1.11 beat PureTech Health's score of 0.00 indicating that Precigen is being referred to more favorably in the media.

Company Overall Sentiment
Precigen Positive
PureTech Health Neutral

Precigen has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Precigen presently has a consensus target price of $13.25, indicating a potential upside of 208.14%. Given Precigen's stronger consensus rating and higher probable upside, equities analysts plainly believe Precigen is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precigen
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

PureTech Health has lower revenue, but higher earnings than Precigen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precigen$9.68M159.27-$250.64M$0.1043.00
PureTech Health$4.66M91.01-$109.74MN/AN/A

Precigen has a net margin of 15.55% compared to PureTech Health's net margin of 0.00%. Precigen's return on equity of 57.93% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Precigen15.55% 57.93% 14.43%
PureTech Health N/A N/A N/A

Summary

Precigen beats PureTech Health on 12 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Nanobiotix?

PureTech Health (NASDAQ:PRTC) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Nanobiotix has a consensus price target of $46.67, suggesting a potential upside of 63.51%. Given Nanobiotix's stronger consensus rating and higher probable upside, analysts plainly believe Nanobiotix is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Nanobiotix has higher revenue and earnings than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health$4.66M91.01-$109.74MN/AN/A
Nanobiotix$36.87M39.45-$27.11MN/AN/A

Company Net Margins Return on Equity Return on Assets
PureTech HealthN/A N/A N/A
Nanobiotix N/A N/A N/A

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Nanobiotix had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Nanobiotix and 0 mentions for PureTech Health. Nanobiotix's average media sentiment score of 0.61 beat PureTech Health's score of 0.00 indicating that Nanobiotix is being referred to more favorably in the news media.

Company Overall Sentiment
PureTech Health Neutral
Nanobiotix Positive

Summary

Nanobiotix beats PureTech Health on 8 of the 11 factors compared between the two stocks.

How does PureTech Health compare to Novavax?

Novavax (NASDAQ:NVAX) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Novavax had 7 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Novavax and 0 mentions for PureTech Health. Novavax's average media sentiment score of 0.50 beat PureTech Health's score of 0.00 indicating that Novavax is being referred to more favorably in the media.

Company Overall Sentiment
Novavax Positive
PureTech Health Neutral

Novavax has higher revenue and earnings than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.12B1.18$440.30M-$0.46N/A
PureTech Health$4.66M91.01-$109.74MN/AN/A

53.0% of Novavax shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PureTech Health has a net margin of 0.00% compared to Novavax's net margin of -18.64%. PureTech Health's return on equity of 0.00% beat Novavax's return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax-18.64% -14.82% -7.55%
PureTech Health N/A N/A N/A

Novavax has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Novavax currently has a consensus target price of $12.33, indicating a potential upside of 53.02%. Given Novavax's stronger consensus rating and higher probable upside, equities analysts clearly believe Novavax is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.20
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Novavax beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Immunocore?

Immunocore (NASDAQ:IMCR) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

84.5% of Immunocore shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Immunocore had 25 more articles in the media than PureTech Health. MarketBeat recorded 25 mentions for Immunocore and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.00 beat Immunocore's score of -0.09 indicating that PureTech Health is being referred to more favorably in the news media.

Company Overall Sentiment
Immunocore Neutral
PureTech Health Neutral

Immunocore has higher revenue and earnings than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunocore$400.02M3.72-$35.51M-$0.65N/A
PureTech Health$4.66M91.01-$109.74MN/AN/A

Immunocore presently has a consensus price target of $52.86, indicating a potential upside of 83.02%. Given Immunocore's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunocore is more favorable than PureTech Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunocore
2 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.50
PureTech Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

PureTech Health has a net margin of 0.00% compared to Immunocore's net margin of -7.48%. PureTech Health's return on equity of 0.00% beat Immunocore's return on equity.

Company Net Margins Return on Equity Return on Assets
Immunocore-7.48% -7.96% -2.93%
PureTech Health N/A N/A N/A

Immunocore has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

Immunocore beats PureTech Health on 9 of the 15 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRTC vs. The Competition

MetricPureTech HealthBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$424.04M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E RatioN/A27.4232.3226.73
Price / Sales91.0116.068.565.71
Price / CashN/A22.9521.0121.90
Price / Book1.384.184.463.72
Net Income-$109.74M-$24.15M$3.52B$393.10M
7 Day PerformanceN/A-7.25%-5.47%-4.73%
1 Month PerformanceN/A-5.98%-4.57%-7.14%
1 Year Performance9.45%-7.72%-1.79%-7.51%

PureTech Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTC
PureTech Health
N/A$17.42
flat
N/AN/A$424.04M$4.66MN/A100
RARE
Ultragenyx Pharmaceutical
2.7013 of 5 stars
$16.51
+2.3%
$29.79
+80.4%
-51.9%$1.68B$730MN/A1,371
PGEN
Precigen
4.2886 of 5 stars
$4.69
+3.7%
$13.50
+188.2%
-11.3%$1.68B$9.68M46.8547
NBTX
Nanobiotix
3.3745 of 5 stars
$32.43
-1.3%
$46.67
+43.9%
+37.2%$1.65B$36.87MN/A97
NVAX
Novavax
1.9562 of 5 stars
$10.04
-1.6%
$12.33
+22.9%
+15.6%$1.65B$1.12BN/A749

Related Companies and Tools


This page (NASDAQ:PRTC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners